Skip to main content

Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic–pharmacodynamic analysis


The objectives of this study were to develop a population pharmacokinetic (PK) model of meropenem, to simulate the percent time above minimum inhibitory concentration (%T > MIC) at various MICs, and to estimate effective dosage regimens by calculating the target attainment rates against various strains of bacteria. A total of 209 plasma samples (1–3 concentrations per patient) were obtained from 98 adult Japanese patients with febrile neutropenia in an open-labeled Phase 3 study. The final population PK model was fit to a two-compartment model with zero-order input. Creatinine clearance had a positive significant correlation with CL. Gender had a significant effect on Vc; however, this effect was small, and the PK profile in male patients was similar to that in female patients. The population PK parameters developed in this study are useful in simulating PK profiles of meropenem at various dosage regimens precisely for calculation of %T > MIC. The PK–PD analysis indicated that 0.5 g every 6 h (q6h) was more effective than 1 g q12h, although provided 2 g per day in total. A meropenem dosage regimen of 1 g q8h and/or longer infusion duration was better against a pathogen of comparatively low sensitivity, Pseudomonas aeruginosa (for MIC ≥2 μg/ml). Although causative bacteria were identified in a small number of patients, the target attainment rates at 75%T > MIC (89%) were comparable to microbiological response (89%). The present PK–PD analyses under various conditions are useful in the treatment of febrile neutropenia.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003;43:1116–23.

    PubMed  Article  CAS  Google Scholar 

  2. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004;26:1187–98.

    PubMed  Article  CAS  Google Scholar 

  3. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006;46:1171–8.

    PubMed  Article  CAS  Google Scholar 

  4. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antibicrobial Agents. 2006;28:62–8.

    Article  CAS  Google Scholar 

  5. Filho LS, Eagye KJ, Kuti JL, Nicolau DP. Addressing resistance evolution in Pseudomonas aeruginosa using pharmacodynamic modeling: application to meropenem dosage and combination therapy. Clin Microbiol Infect. 2007;13:579–85.

    Article  Google Scholar 

  6. Watanabe A, Fujimura S, Kikuchi T, Gomi K, Fuse K, Nukiwa T. Evaluation of dosing designs of carbapenems for severe respiratory infection using Monte Carlo simulation. J Infect Chemother. 2007;13:332–40.

    PubMed  Article  CAS  Google Scholar 

  7. Mikamo H, Totsuka K. The comparison of optimized pharmacodynamic dosing strategy for meropenem using Monte Carlo simulation. Jpn J Antibiot. 2005;58:159–67.

    PubMed  Google Scholar 

  8. Lee DG, Choi SM, Shin WS, Lah HO, Yim DS. Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents. 2006;28:333–9.

    PubMed  Article  CAS  Google Scholar 

  9. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, et al. Pharmacodynamic target attainment of seven antimicrobials against gram-negative bacteria collected from China in 2003–2004. Int J Antimicrob Agents. 2007;30:452–7.

    PubMed  Article  CAS  Google Scholar 

  10. Ohata Y, Tomita Y, Nakayama M, Kozuki T, Sunakawa S, Tanigawara Y. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic consideration. Drug Metab Pharmacokinet (in press).

  11. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51:1725–30.

    PubMed  Article  CAS  Google Scholar 

  12. Ikawa K, Morikawa N, Ohgi H, Ikeda K, Sueda T, Taniwaki M, et al. Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J Infect Chemother. 2010;16:25–32.

    PubMed  Article  CAS  Google Scholar 

  13. Ariano RE, Nyhlén A, Donnelly JP, Sitar DS, Harding GKM, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother. 2005;39:32–8.

    PubMed  CAS  Google Scholar 

  14. Yamaguchi K, Ishii Y, Iwata M, Watanabe N, Uehara N, Yasujima M, et al. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn J Antibiot. 2007;60:344–77.

    PubMed  CAS  Google Scholar 

  15. Clinical phase 3 study of meropenem. Pharmaceuticals and medical devices agency, Japan [CTD, common technical document] 2010.

  16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. In: Approved standard M7-A7. CLSI, Wayne, PA, 2006.

  17. Guidance for Industry: Population Pharmacokinetics. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (U.S.) (February 1999).

  18. Guideline on Reporting the Results of Population Pharmacokinetic Analyses. European Medicines Agency (UK) (January 2008).

  19. Nakajima M, Uematsu T, Kanamaru M. Clinical phase Ι study of meropenem. Chemotherapy 1992;40(S-I):258–275.

    Google Scholar 

  20. Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992;36:1532–7.

    PubMed  CAS  Google Scholar 

  21. Chimata M, Nagase M, Suzuki Y, Shimomura M, Kakuta S. Pharmacokinetics of meropenem in patients with carious degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother. 1993;37:229–33.

    PubMed  CAS  Google Scholar 

  22. Shibayama T, Sugiyama D, Kamiyama E, Tokui T, Hirota T, Ikeda T. Characterization of CS-023 (R04908463), a novel parenteral carbapenem antibiotic, and meropenem as substrates of human renal transporters. Drug Metab Pharmacokinet. 2007;22(1):41–7.

    PubMed  Article  CAS  Google Scholar 

  23. Tsumura R, Ikawa K, Morikawa M, Ikeda K, Shibukawa M, Iida K, et al. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. J Chemother. 2008;20(5):615–21.

    PubMed  CAS  Google Scholar 

  24. Hathorn WJ, Lyke K. Empirical treatment of febrile neutropenia: Evolution of current therapeutic approaches. Clin Infect Dis 1997;24(suppl 2):s256–s265.

    Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Yusuke Tanigawara.

About this article

Cite this article

Ohata, Y., Tomita, Y., Nakayama, M. et al. Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic–pharmacodynamic analysis. J Infect Chemother 17, 831–841 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • Meropenem
  • %T > MIC
  • Pharmacokinetics
  • Pharmacodynamics
  • Febrile neutropenia
  • Monte Carlo simulation